Crizotinib targets anaplastic lymphoma kinase (ALK) and the TKs of MET, and the RON (macrophage-stimulating 1 receptor) and ROS (ROS proto-oncogene 1, receptor tyrosine kinase) receptors and is an FDA-approved treatment for ALK-rearranged NSCLC.330 Crizotinib has attractive efficacy in prolonging the survival of patients with NSCLC.331 Although there is a lack of clinical evidence for crizotinib in CRC, a series of phase I and II trials are in progress. This evidence concerns the gene MST1R and colorectal carcinoma.